Transforming Retinal Disease Care: Next-Generation Therapies for nAMD and DME to Reduce Burden and Optimize Outcomes
Dilsher S. Dhoot, MD, discusses how second-generation anti-VEGF therapies like aflibercept 8 mg and faricimab demonstrate superior efficacy and durability in treating neovascular age-related macular degeneration (nAMD) and diabetic macular edema (DME) cases, allowing treatment intervals to extend by 2 to 3 weeks, improving anatomical outcomes, and reducing patient treatment burden compared with first-generation agents.
EP. 1: Improved Retinal Drying and Treatment Durability In nAMD With Aflibercept 8 mg
June 3rd 2025Dilsher S. Dhoot, MD, discusses how newer anti-VEGF treatments, particularly aflibercept 8 mg, can provide improved anatomic outcomes and extended treatment intervals for patients with neovascular age-related macular degeneration who show persistent subretinal fluid despite treatment with first-generation agents.
EP. 2: Rapid Improvements In DME With Next-Generation Anti-VEGF Therapies: Case Highlights
June 3rd 2025Dilsher S. Dhoot, MD, discusses how second-generation anti-VEGF agents like aflibercept 8 mg and faricimab demonstrate significant efficacy in treating diabetic macular edema (DME), allowing for extended treatment intervals of 9 to 10 weeks compared to monthly dosing with earlier agents, while improving anatomic outcomes and visual acuity.
